Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Mounjaro Frenzy: Overwhelmed With Queries About Weight-Loss Drug, Doctors Warn Against Cosmetic Use
The growing interest in Mounjaro shows an increasing awareness of metabolic health, which is a positive trend. However, ...
Futurism on MSN20h
Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal
Hims — the next gen telehealth startup that made waves by taking the eye contact out of erectile dysfunction treatment. Of ...
More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs
But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...